Preventing Chemotherapy-Induced Nausea and Vomiting
ALOXI (palonosetron HCI injection) is an anti-nausea medication
also known as an antiemetic. In adults, ALOXI is used to help prevent symptoms
nausea and vomiting (CINV) in a single intravenous (IV) dose by blocking
the effects of serotonin.
Depending on the type of chemotherapy you get, your chance of experiencing CINV
on the same day, known as acute CINV, can be very high. You may also experience
delayed CINV in the days following your treatment. ALOXI is used to prevent both
delayed CINV in patients receiving moderately emetogenic chemotherapy and
acute CINV in patients receiving
highly emetogenic chemotherapy.
If you experience CINV during one chemotherapy cycle, you are more likely to experience
CINV again during a later cycle. Speak to your health care team on the importance of trying to prevent these symptoms before they start.
Powerful CINV prevention in a single dose
ALOXI is given as a single intravenous (IV) injection administered by a health care
professional about 30 minutes before the start of chemotherapy treatment. The single
ALOXI injection is likely to be given through the same IV line as your chemotherapy.
From the first cycle, ALOXI can help prevent nausea and vomiting for:
- One day following chemotherapy that is highly likely to cause nausea and vomiting
- Up to five days following chemotherapy that is moderately likely to cause nausea and vomiting
ALOXI for CINV Prevention
Your doctor or nurse will help you determine if using ALOXI should be part of your
chemotherapy-induced nausea and vomiting prevention plan. Talk to your doctor and
do not take ALOXI if you are allergic to any of its ingredients. The ingredients
in ALOXI are:
Active ingredient: Palonosetron hydrochloride
Inactive ingredients: mannitol, disodium edetate, and citrate buffer
Potential side effects of ALOXI include headache and constipation. For a complete
list of side effects Please read the Full Product Information and discuss it with your doctor
or health care professional.